Other languages Lipigon Pharmaceuticals AB

Equities

LPGO

SE0015382072

Delayed Nasdaq Stockholm Other stock markets 07:39:51 2024-07-12 am EDT			5-day change	1st Jan Change
0.3395 ^SEK	+0.15%		+9.52%	-21.23%

Jul. 09	Lipigon Pharmaceuticals Receives Milestone Payment of USD 1 Million from Leaderna Therapeutics Ltd for Approval of Phase I Bridging Study	CI
Jun. 20	Lipigon Pharmaceuticals AB Announces ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lipigon Pharmaceuticals Receives Milestone Payment of USD 1 Million from Leaderna Therapeutics Ltd for Approval of Phase I Bridging Study	Jul. 09
Lipigon Pharmaceuticals AB Announces ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes	Jun. 20
Lipigon Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 28
Lipigon Pharmaceuticals AB and Leaderna Therapeutics Collaboration on Lipisense® Shows Good Progress	May. 15
Lipigon Pharmaceuticals AB Collaborates with University of Washington on Lung Damage Project	May. 14
Lipigon Collaborates with University of Washington on Lung Damage Project	May. 14
Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22
Lipigon Pharmaceuticals’ Lipisense Gets Swedish Regulators' Nod for Mid-stage Study	Feb. 07
The Swedish Medical Products Agency Approves Lipigon's Phase II Study with Lipisense	Feb. 07
Lipigon Pharmaceuticals AB Announces Lipisense Progressing to Phase II Trials	Dec. 12
Lipigon Pharmaceuticals AB Reports A Statically Confirms reduction of target protein ANGPTL4 after repeate treatment with Lipisense ®	Nov. 23
Lipigon Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 23
Lipigon Applies for Clinical Trial Phase II for Lipisense	Nov. 13
Lipigon Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29
Lipigon Pharmaceuticals AB Announces Positive Safety Results and Encouraging Target Engagement Data from the Phase I Lipisense Trial	23-07-12
Lipigon Announces Development and License Agreement with Leaderna Therapeutics Ltd	23-06-27
Lipigon Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25
Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28
Lipigon Pharmaceuticals AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28
Lipigon Announces Further Positive Data from Phase I Trial of Lipisense	23-01-19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lipigon Pharmaceuticals AB

Equities

LPGO

SE0015382072

Other languages

Filters